Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
256.68
+18.00 (7.54%)
At close: May 12, 2025, 4:00 PM
256.68
0.00 (0.00%)
After-hours: May 12, 2025, 7:00 PM EDT
Bio-Rad Laboratories Revenue
Bio-Rad Laboratories had revenue of $585.40M in the quarter ending March 31, 2025, a decrease of -4.16%. This brings the company's revenue in the last twelve months to $2.54B, down -2.46% year-over-year. In the year 2024, Bio-Rad Laboratories had annual revenue of $2.57B, down -3.92%.
Revenue (ttm)
$2.54B
Revenue Growth
-2.46%
P/S Ratio
2.64
Revenue / Employee
$330,013
Employees
7,700
Market Cap
6.98B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.57B | -104.70M | -3.92% |
Dec 31, 2023 | 2.67B | -131.00M | -4.67% |
Dec 31, 2022 | 2.80B | -120.35M | -4.12% |
Dec 31, 2021 | 2.92B | 376.92M | 14.81% |
Dec 31, 2020 | 2.55B | 233.97M | 10.12% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BIO News
- 10 days ago - Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Bio-Rad Reports First-Quarter 2025 Financial Results - Business Wire
- 3 months ago - Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results - Business Wire
- 3 months ago - Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies - Business Wire
- 3 months ago - Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 - Business Wire
- 4 months ago - Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests - Business Wire
- 4 months ago - Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference - Business Wire